Presentation

Company Profile
Camurus Swedish pharmaceutical company committed to developing and commercializing long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. The company's product pipeline represents a mix of in-house and partnered projects in different development phases, based on the proprietary FluidCrystal® injection-depot technology. Camurus has two approved products: Buvidal for the treatment of opioid dependence and episil® oral liquid for the treatment of inflammatory and painful conditions in the oral cavity.

Recent highlights
Camurus delivered a strong Q2 report, posting revenue growth of 71% year-on-year to SEK 138m (81). During Q2, the company received market approval of a new higher dose (160mg) of Buvidal® in Australia, EU and UK. Furthermore, FDA accepted the NDA filing and set a PDUFA date for market approval of Brixadi to 15 December 2021. The company announced that results from two studies were published in reputable journals. The DEBUT study showed improved treatment results with Buvidal compared to daily standard treatment. The UNLOC-T study showed good treatment results with Buvidal in custodial setting.

Outlook
During 2021, the focus of the company lies in progressing the development of the different clinical programmes. At the same time, the company continuously pursues expansion of the marketed product segment, through submissions of different applications for approval in new countries as well as label/dose expansions.